Imunon, Inc. (IMNN) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Imunon, Inc. is a clinical-stage biotechnology company developing non-viral DNA therapeutics. Its lead program, IMNN-001, is a DNA-based immunotherapy for advanced ovarian cancer currently in a Phase 3 trial (OVATION 3). The company also maintains a vaccine platform (PlaCCine) with a completed Phase 1 study for a COVID-19 booster (IMNN-101).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2.81) million | $(7.06) million | $(6.84) million |
| Operating Expenses | $(2.79) million | $(7.10) million | $(6.91) million |
| Cash & Equivalents | $6.86 million (as of June 30, 2026) | ||
| Restricted Cash | $5.00 million (collateral for debt) | ||
| Total Debt (Notes A & B) | ~$7.03 million principal | ||
| Working Capital | $3.91 million |
Material Changes vs. Prior Period
- Financing Activity: In June 2026, the company closed a $10 million transaction with Streeterville Capital, LLC. This included $2.5 million in Series A Preferred Stock, a $2.72 million Secured Promissory Note (A-1), and a $5.0 million Secured Promissory Note (B). $5.0 million of the proceeds were placed in a restricted cash collateral account.
- Expense Trends: Research and Development (R&D) expenses increased 12.1% year-over-year for the six months ended June 30, 2026, driven by manufacturing and clinical supply costs for the OVATION 3 Phase 3 trial. General and Administrative (G&A) expenses decreased 6.4% due to reduced professional fees.
- Capital Structure: The company issued 250 shares of Series A Preferred Stock and incurred significant new debt obligations not present in the prior year.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has determined there is substantial doubt about the company's ability to continue as a going concern. The company has incurred cumulative net losses of approximately $428 million and relies on raising additional capital to fund operations for the next 12 months.
- Clinical Progress: The Phase 3 OVATION 3 trial for IMNN-001 is on track, with enrollment exceeding forecasts. The independent Data Monitoring Committee recommended continuation of the trial in June 2026. Preliminary data from the MRD study showed lower MRD-positive rates in the treatment arm compared to control.
- Liquidity Strategy: The company plans to raise funds through its At-The-Market (ATM) program, private equity sales, and debt facilities. However, there is no assurance that funding will be available on acceptable terms.
- Risks: Key risks include the inability to raise capital, failure of clinical trials, regulatory hurdles, and the high cost of development relative to current cash reserves.
Investor Verification Checklist
- Cash Runway: Verify the burn rate against the $6.86 million in unrestricted cash to confirm the timeline for the next capital raise.
- Debt Covenants: Review the terms of the new Notes A-1 and B, specifically the redemption features, interest rates (8% and 5%), and the impact of the $5 million restricted cash on liquidity.
- Phase 3 Enrollment: Monitor the enrollment rate of the OVATION 3 trial to ensure it meets the projected completion date of H1 2029.
- Preferred Stock Terms: Examine the rights and preferences of the newly issued Series A Preferred Stock and the waiver of redemption rights.
- ATM Capacity: Check the remaining capacity under the At-The-Market offering agreement and recent sales activity.